Excedrin 250 mg /250 mg /65 mg film-coated tablets * Pharmacy Only: Non-prescription
Company:
GlaxoSmithKline Consumer Healthcare (Ireland) LtdStatus:
No Recent UpdateLegal Category:
Supply through pharmacy onlyActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 18 January 2023
File name
63c7fe0cb8dca.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Updated on 18 January 2023
File name
63c7fa7edb0f5.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Supply through pharmacy only
Updated on 18 January 2023
File name
6335771cbd735.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Supply through pharmacy only
Updated on 29 September 2022
File name
6335771cbd735.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Addition of CRSF blister packaging.
Updated on 04 September 2020
File name
ie-pl-excedrin-safety update - II-043-G approved 4th Sept 2020_1599234829.pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - dose and frequency
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
Updated on 04 September 2020
File name
ie-spc-excedrin-safety update- II-43-G approved 4th Sept 2020_1599234385.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.6 - Special precautions for disposal and other handling
Legal category:Supply through pharmacy only
Updated on 28 March 2019
File name
ie-mockup-pl-61(3)Famar-190204EM_1553774916.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 04 January 2019
File name
ie-spc-excedrin-proposed-clean-dec2018-medie_1546620580.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Updated on 04 January 2019
File name
ie-spc-excedrin-proposed-clean-dec2018-medie_1546620456.pdf
Reasons for updating
- New SPC for new product
Legal category:Supply through pharmacy only
Updated on 06 June 2017
File name
PIL_16707_876.pdf
Reasons for updating
- New PIL for new product
Updated on 06 June 2017
Reasons for updating
- Change to section 6 - date of revision
- Change to name of medicinal product
Updated on 03 May 2016
Reasons for updating
- New PIL for medicines.ie